These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7923313)

  • 1. Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance.
    Uchida K; Azukizawa S; Kigoshi T; Nakano S; Kaneko M; Morimoto S; Matsui A
    Clin Ther; 1994; 16(3):466-70. PubMed ID: 7923313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study].
    Widimský J; Fedelesová V; Uhlír O
    Vnitr Lek; 1995 Jul; 41(7):441-4. PubMed ID: 7571476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
    Sasaki J; Kajiyama G; Kusukawa R; Shichiri M; Sunaga T; Mashiba H; Tanaka N; Nonaka K; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):366-70. PubMed ID: 7582390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension].
    Lin J; Chen D; Wu K
    Zhonghua Yi Xue Za Zhi; 1998 Mar; 78(3):200-2. PubMed ID: 10923530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of perindopril treatment on plasma and urine of kallikrein activity and the stable metabolite of prostaglandin E2 in patients with essential hypertension.
    Zacharieva S; Torbova S; Orbetzova M; Borissova AM; Andonova K; Sheitanova S
    Methods Find Exp Clin Pharmacol; 1996 Apr; 18(3):205-9. PubMed ID: 8738072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function, glycaemic control and perindopril in diabetic patients.
    Brichard S; Ketelslegers JM; Lambert AE
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():57-61. PubMed ID: 2505714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [24-hour effect and tolerance for perindopril (Prestarium) in mild and moderate essential hypertension].
    Widimský J; Cihák R; Fedelesová V; Lefflerová K; Mayer O; Uhlír O
    Vnitr Lek; 1992 Nov; 38(11):1066-71. PubMed ID: 1494869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of urapidil on blood pressure, renal hemodynamics, lipid and glucose metabolism].
    Sanjuliani AF; Fagundes VG; Francischetti EA
    Arq Bras Cardiol; 1995 Jul; 65(1):59-63. PubMed ID: 8546598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
    Middeke M; Richter WO; Schwandt P; Holzgreve H
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate.
    Al-Waili N
    Eur J Med Res; 2003 Jul; 8(7):295-303. PubMed ID: 12911866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Celiprolol improves glucose metabolism in essential hypertension].
    Oksa A; Fedelesová V; Spustová V; Dzúrik R
    Vnitr Lek; 1998 Feb; 44(2):63-7. PubMed ID: 9820078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
    Shionoiri H; Gotoh E; Ito T; Hata T; Iwatsubo H; Takegawa K; Ogihara T; Mikami H; Ikegami H; Otsuka A
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S91-5. PubMed ID: 7908168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical review of perindopril in the treatment of hypertension.
    Lerebours G; Antony I
    Can J Cardiol; 1994 Nov; 10 Suppl D():3D-7D. PubMed ID: 7954037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily perindopril versus slow release diltiazem in the treatment of mild to moderate essential hypertension. Canadian Study Group on Perindopril.
    Can J Cardiol; 1994 Nov; 10 Suppl D():8D-12D. PubMed ID: 7954041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ambulatory registration of arterial pressure during treatment with perindopril. Effects on systolic pressure and hemodynamic implications].
    Santoni JP; Asmar RG; Bizot-Espiard JG; Safar M
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():51-6. PubMed ID: 2505713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.
    Letellier P; Overlack A; Agnes E; Desche P
    J Hum Hypertens; 1994 Feb; 8(2):145-9. PubMed ID: 8207741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
    Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
    Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of spirapril and atenolol: results from a randomized, long-term study.
    Hakamäki T; Lehtonen A
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):227-30. PubMed ID: 9208336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.